Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
36 studies found for:    Neuromyelitis Optica
Show Display Options
Rank Status Study
1 Recruiting A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Transverse Myelitis;   Optic Neuritis
Intervention:
2 Recruiting Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
Conditions: Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorders
Intervention: Other: Magnetic Resonance Imaging
3 Completed
Has Results
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Devic's Disease
Intervention: Drug: Eculizumab
4 Unknown  Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
Conditions: Devic's Syndrome;   Devic's Neuromyelitis Optica;   Devic Syndrome;   Devic's Disease;   Devic Disease
Intervention: Biological: Autologous mesenchymal stem cells
5 Recruiting The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Conditions: Neuromyelitis Optica Spectrum Disorders;   Neuromyelitis Optica Spectrum Related Disorders
Intervention:
6 Recruiting Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Ublituximab
7 Active, not recruiting Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Procedure: AHSCT
8 Completed Neuromyelitis Optica (NMO) & Cetirizine
Condition: Neuromyelitis Optica
Intervention: Drug: cetirizine
9 Unknown  Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
Conditions: Progressive Multiple Sclerosis;   Neuromyelitis Optica.
Intervention: Biological: human umbilical cord mesenchymal stem cells
10 Unknown  Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
Condition: Neuromyelitis Optica
Interventions: Drug: Alpha1-antitrypsin;   Drug: methylprednisolone
11 Recruiting Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: NPB-01
12 Completed
Has Results
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Condition: Neuromyelitis Optica
Intervention: Drug: C1-esterase inhibitor (Cinryze)
13 Active, not recruiting Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Bortezomib
14 Unknown  Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
Conditions: Multiple Sclerosis;   Neuromyelitis Optica
Intervention:
15 Unknown  Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorders
Intervention: Drug: Mitoxantrone
16 Active, not recruiting Maintenance Plasma Exchange for Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
Intervention: Procedure: Plasma exchange (PLEX)
17 Completed Safety and Tolerability of Rituximab in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Drug: Rituximab
18 Enrolling by invitation Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
Conditions: Neuromyelitis Optica Spectrum Disorders;   Mycophenolate Mofetil;   Efficacy and Safety
Interventions: Drug: Mycophenolate mofetil;   Drug: Prednisone
19 Completed A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
Conditions: Neuromyelitis Optica;   Myelitis, Transverse;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Drug: Mitoxantrone
20 Recruiting A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
Interventions: Biological: MEDI-551;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years